Please assess the completion status of the following clinical trial:

Trial Title: TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed GBM, WHO grade IV. GBM variants and secondary GBM are allowed in any recurrence (including multiple) and have been treated with radiation and chemotherapy.~* Unequivocal evidence of tumor progression during prior bevacizumab treatment per RANO criteria.~* Patient is a candidate for, and agrees to proceed with additional bevacizumab treatment.~* Male or female at least 22 years of age or older.~* Karnofsky Performance Scale (KPS) ≥ 60%.~* Planned treatment with TTFields therapy.~* Women of childbearing potential must have a negative serum or urine pregnancy test within 14 days of treatment.~* Participants of childbearing/reproductive potential must use effective contraception.~* Participants must be able to understand and willing to comply with protocol requirements as assessed by the investigator.~* Signed informed consent according to institutional guidelines prior to registration.~Exclusion Criteria:~* Inability to undergo brain MRI due to medical or personal reasons.~* Currently receiving investigational agents that are intended as treatments of recurrent GBM.~* Skull defect such as missing bone or bullet fragments.~* Uncontrolled intercurrent illness including, but not limited to symptomatic congestive heart failure, unstable angina pectoris, heart attack within the previous 12 months, stroke (except for TIA) within the previous 6 months, or psychiatric illness/social situations that would limit compliance with study requirements.~* Intracranial hemorrhage except for tumor associated micro hemorrhage.~* Women who are pregnant or breastfeeding.~* Implanted pacemaker, programmable shunts, defibrillator, deep brain stimulator, vagus nerve stimulator, and other implanted electronic devices in the brain or the spinal cord.~* Tumor located entirely in the infratentorium.~* History of hypersensitivity to hydrogel.

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Optune+Pulsed Bevacizumab (Type: EXPERIMENTAL): The subjects will undergo 12 months of planned continuous treatment with Optune. The treatment will begin at week 0 and will be continuous throughout the study. Pulsed bevacizumab dosing is defined by at least one cycle on and at least one cycle off. A cycle is defined as 8 weeks in length. If after one cycle on, there is no evidence of a repeat response; bevacizumab will be continued for one more cycle. If after two cycles on, there is no repeat response; bevacizumab will be continued with or without other standard chemotherapy until death. If after at least one cycle on, there is evidence of repeat response, bevacizumab will be discontinued for at least one cycle. In addition, the following will be performed: Bevacizumab will be given, physical examination and quality of life questionnaires will be performed and brain MRI.

Based on this trial design, predict the completion outcome and termination type (if applicable).